Commentary|Podcasts|September 18, 2023
Managed Care Cast Presents: Stakeholders Summit—Biosimilars in Inflammatory Diseases, Part 2
Author(s)Laura Joszt, MA
In part 2 of this 2-part podcast, a panel of experts discusses challenges with biosimilar uptake, interchangeability studies, patient and provider education.
Advertisement
Today we are bringing you part 2 of a 2-part sponsored podcast series discussing the use of biosimilars in inflammatory diseases. The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute.
The conversation for today’s podcast includes challenges with biosimilar uptake, interchangeability studies, patient and provider education.
Listen above or through one of these podcast services:
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
3
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
4
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
5